Audit 406039

FY End
2025-09-30
Total Expended
$63.02M
Findings
401
Programs
81
Year: 2025 Accepted: 2026-06-30

Organization Exclusion Status:

Checking exclusion status...

Findings

ID Ref Severity Repeat Requirement
1221787 2025-001 Material Weakness Yes B
1221788 2025-001 Material Weakness Yes B
1221789 2025-001 Material Weakness Yes B
1221790 2025-001 Material Weakness Yes B
1221791 2025-001 Material Weakness Yes B
1221792 2025-001 Material Weakness Yes B
1221793 2025-001 Material Weakness Yes B
1221794 2025-001 Material Weakness Yes B
1221795 2025-001 Material Weakness Yes B
1221796 2025-001 Material Weakness Yes B
1221797 2025-001 Material Weakness Yes B
1221798 2025-001 Material Weakness Yes B
1221799 2025-001 Material Weakness Yes B
1221800 2025-001 Material Weakness Yes B
1221801 2025-001 Material Weakness Yes B
1221802 2025-001 Material Weakness Yes B
1221803 2025-001 Material Weakness Yes B
1221804 2025-001 Material Weakness Yes B
1221805 2025-001 Material Weakness Yes B
1221806 2025-001 Material Weakness Yes B
1221807 2025-001 Material Weakness Yes B
1221808 2025-001 Material Weakness Yes B
1221809 2025-001 Material Weakness Yes B
1221810 2025-001 Material Weakness Yes B
1221811 2025-001 Material Weakness Yes B
1221812 2025-001 Material Weakness Yes B
1221813 2025-001 Material Weakness Yes B
1221814 2025-001 Material Weakness Yes B
1221815 2025-001 Material Weakness Yes B
1221816 2025-001 Material Weakness Yes B
1221817 2025-001 Material Weakness Yes B
1221818 2025-001 Material Weakness Yes B
1221819 2025-001 Material Weakness Yes B
1221820 2025-001 Material Weakness Yes B
1221821 2025-001 Material Weakness Yes B
1221822 2025-001 Material Weakness Yes B
1221823 2025-001 Material Weakness Yes B
1221824 2025-001 Material Weakness Yes B
1221825 2025-001 Material Weakness Yes B
1221826 2025-001 Material Weakness Yes B
1221827 2025-001 Material Weakness Yes B
1221828 2025-001 Material Weakness Yes B
1221829 2025-001 Material Weakness Yes B
1221830 2025-001 Material Weakness Yes B
1221831 2025-001 Material Weakness Yes B
1221832 2025-001 Material Weakness Yes B
1221833 2025-001 Material Weakness Yes B
1221834 2025-001 Material Weakness Yes B
1221835 2025-001 Material Weakness Yes B
1221836 2025-001 Material Weakness Yes B
1221837 2025-001 Material Weakness Yes B
1221838 2025-001 Material Weakness Yes B
1221839 2025-001 Material Weakness Yes B
1221840 2025-001 Material Weakness Yes B
1221841 2025-001 Material Weakness Yes B
1221842 2025-001 Material Weakness Yes B
1221843 2025-001 Material Weakness Yes B
1221844 2025-001 Material Weakness Yes B
1221845 2025-001 Material Weakness Yes B
1221846 2025-001 Material Weakness Yes B
1221847 2025-001 Material Weakness Yes B
1221848 2025-001 Material Weakness Yes B
1221849 2025-001 Material Weakness Yes B
1221850 2025-001 Material Weakness Yes B
1221851 2025-001 Material Weakness Yes B
1221852 2025-001 Material Weakness Yes B
1221853 2025-001 Material Weakness Yes B
1221854 2025-001 Material Weakness Yes B
1221855 2025-001 Material Weakness Yes B
1221856 2025-001 Material Weakness Yes B
1221857 2025-001 Material Weakness Yes B
1221858 2025-001 Material Weakness Yes B
1221859 2025-001 Material Weakness Yes B
1221860 2025-001 Material Weakness Yes B
1221861 2025-001 Material Weakness Yes B
1221862 2025-001 Material Weakness Yes B
1221863 2025-001 Material Weakness Yes B
1221864 2025-001 Material Weakness Yes B
1221865 2025-001 Material Weakness Yes B
1221866 2025-001 Material Weakness Yes B
1221867 2025-001 Material Weakness Yes B
1221868 2025-001 Material Weakness Yes B
1221869 2025-001 Material Weakness Yes B
1221870 2025-001 Material Weakness Yes B
1221871 2025-001 Material Weakness Yes B
1221872 2025-001 Material Weakness Yes B
1221873 2025-001 Material Weakness Yes B
1221874 2025-001 Material Weakness Yes B
1221875 2025-001 Material Weakness Yes B
1221876 2025-001 Material Weakness Yes B
1221877 2025-001 Material Weakness Yes B
1221878 2025-001 Material Weakness Yes B
1221879 2025-001 Material Weakness Yes B
1221880 2025-001 Material Weakness Yes B
1221881 2025-001 Material Weakness Yes B
1221882 2025-001 Material Weakness Yes B
1221883 2025-001 Material Weakness Yes B
1221884 2025-001 Material Weakness Yes B
1221885 2025-001 Material Weakness Yes B
1221886 2025-001 Material Weakness Yes B
1221887 2025-001 Material Weakness Yes B
1221888 2025-001 Material Weakness Yes B
1221889 2025-001 Material Weakness Yes B
1221890 2025-001 Material Weakness Yes B
1221891 2025-001 Material Weakness Yes B
1221892 2025-001 Material Weakness Yes B
1221893 2025-001 Material Weakness Yes B
1221894 2025-001 Material Weakness Yes B
1221895 2025-001 Material Weakness Yes B
1221896 2025-001 Material Weakness Yes B
1221897 2025-001 Material Weakness Yes B
1221898 2025-001 Material Weakness Yes B
1221899 2025-001 Material Weakness Yes B
1221900 2025-001 Material Weakness Yes B
1221901 2025-001 Material Weakness Yes B
1221902 2025-001 Material Weakness Yes B
1221903 2025-001 Material Weakness Yes B
1221904 2025-001 Material Weakness Yes B
1221905 2025-001 Material Weakness Yes B
1221906 2025-001 Material Weakness Yes B
1221907 2025-001 Material Weakness Yes B
1221908 2025-001 Material Weakness Yes B
1221909 2025-001 Material Weakness Yes B
1221910 2025-001 Material Weakness Yes B
1221911 2025-001 Material Weakness Yes B
1221912 2025-001 Material Weakness Yes B
1221913 2025-001 Material Weakness Yes B
1221914 2025-001 Material Weakness Yes B
1221915 2025-001 Material Weakness Yes B
1221916 2025-001 Material Weakness Yes B
1221917 2025-001 Material Weakness Yes B
1221918 2025-001 Material Weakness Yes B
1221919 2025-001 Material Weakness Yes B
1221920 2025-001 Material Weakness Yes B
1221921 2025-001 Material Weakness Yes B
1221922 2025-001 Material Weakness Yes B
1221923 2025-001 Material Weakness Yes B
1221924 2025-001 Material Weakness Yes B
1221925 2025-001 Material Weakness Yes B
1221926 2025-001 Material Weakness Yes B
1221927 2025-001 Material Weakness Yes B
1221928 2025-001 Material Weakness Yes B
1221929 2025-001 Material Weakness Yes B
1221930 2025-001 Material Weakness Yes B
1221931 2025-001 Material Weakness Yes B
1221932 2025-001 Material Weakness Yes B
1221933 2025-001 Material Weakness Yes B
1221934 2025-001 Material Weakness Yes B
1221935 2025-001 Material Weakness Yes B
1221936 2025-001 Material Weakness Yes B
1221937 2025-001 Material Weakness Yes B
1221938 2025-001 Material Weakness Yes B
1221939 2025-001 Material Weakness Yes B
1221940 2025-001 Material Weakness Yes B
1221941 2025-001 Material Weakness Yes B
1221942 2025-001 Material Weakness Yes B
1221943 2025-001 Material Weakness Yes B
1221944 2025-001 Material Weakness Yes B
1221945 2025-001 Material Weakness Yes B
1221946 2025-001 Material Weakness Yes B
1221947 2025-001 Material Weakness Yes B
1221948 2025-001 Material Weakness Yes B
1221949 2025-001 Material Weakness Yes B
1221950 2025-001 Material Weakness Yes B
1221951 2025-001 Material Weakness Yes B
1221952 2025-001 Material Weakness Yes B
1221953 2025-001 Material Weakness Yes B
1221954 2025-001 Material Weakness Yes B
1221955 2025-001 Material Weakness Yes B
1221956 2025-001 Material Weakness Yes B
1221957 2025-001 Material Weakness Yes B
1221958 2025-001 Material Weakness Yes B
1221959 2025-001 Material Weakness Yes B
1221960 2025-001 Material Weakness Yes B
1221961 2025-001 Material Weakness Yes B
1221962 2025-001 Material Weakness Yes B
1221963 2025-001 Material Weakness Yes B
1221964 2025-001 Material Weakness Yes B
1221965 2025-001 Material Weakness Yes B
1221966 2025-001 Material Weakness Yes B
1221967 2025-001 Material Weakness Yes B
1221968 2025-001 Material Weakness Yes B
1221969 2025-001 Material Weakness Yes B
1221970 2025-001 Material Weakness Yes B
1221971 2025-001 Material Weakness Yes B
1221972 2025-001 Material Weakness Yes B
1221973 2025-001 Material Weakness Yes B
1221974 2025-001 Material Weakness Yes B
1221975 2025-001 Material Weakness Yes B
1221976 2025-001 Material Weakness Yes B
1221977 2025-001 Material Weakness Yes B
1221978 2025-001 Material Weakness Yes B
1221979 2025-001 Material Weakness Yes B
1221980 2025-001 Material Weakness Yes B
1221981 2025-001 Material Weakness Yes B
1221982 2025-001 Material Weakness Yes B
1221983 2025-001 Material Weakness Yes B
1221984 2025-001 Material Weakness Yes B
1221985 2025-001 Material Weakness Yes B
1221986 2025-002 Material Weakness Yes F
1221987 2025-002 Material Weakness Yes F
1221988 2025-002 Material Weakness Yes F
1221989 2025-002 Material Weakness Yes F
1221990 2025-002 Material Weakness Yes F
1221991 2025-002 Material Weakness Yes F
1221992 2025-002 Material Weakness Yes F
1221993 2025-002 Material Weakness Yes F
1221994 2025-002 Material Weakness Yes F
1221995 2025-002 Material Weakness Yes F
1221996 2025-002 Material Weakness Yes F
1221997 2025-002 Material Weakness Yes F
1221998 2025-002 Material Weakness Yes F
1221999 2025-002 Material Weakness Yes F
1222000 2025-002 Material Weakness Yes F
1222001 2025-002 Material Weakness Yes F
1222002 2025-002 Material Weakness Yes F
1222003 2025-002 Material Weakness Yes F
1222004 2025-002 Material Weakness Yes F
1222005 2025-002 Material Weakness Yes F
1222006 2025-002 Material Weakness Yes F
1222007 2025-002 Material Weakness Yes F
1222008 2025-002 Material Weakness Yes F
1222009 2025-002 Material Weakness Yes F
1222010 2025-002 Material Weakness Yes F
1222011 2025-002 Material Weakness Yes F
1222012 2025-002 Material Weakness Yes F
1222013 2025-002 Material Weakness Yes F
1222014 2025-002 Material Weakness Yes F
1222015 2025-002 Material Weakness Yes F
1222016 2025-002 Material Weakness Yes F
1222017 2025-002 Material Weakness Yes F
1222018 2025-002 Material Weakness Yes F
1222019 2025-002 Material Weakness Yes F
1222020 2025-002 Material Weakness Yes F
1222021 2025-002 Material Weakness Yes F
1222022 2025-002 Material Weakness Yes F
1222023 2025-002 Material Weakness Yes F
1222024 2025-002 Material Weakness Yes F
1222025 2025-002 Material Weakness Yes F
1222026 2025-002 Material Weakness Yes F
1222027 2025-002 Material Weakness Yes F
1222028 2025-002 Material Weakness Yes F
1222029 2025-002 Material Weakness Yes F
1222030 2025-002 Material Weakness Yes F
1222031 2025-002 Material Weakness Yes F
1222032 2025-002 Material Weakness Yes F
1222033 2025-002 Material Weakness Yes F
1222034 2025-002 Material Weakness Yes F
1222035 2025-002 Material Weakness Yes F
1222036 2025-002 Material Weakness Yes F
1222037 2025-002 Material Weakness Yes F
1222038 2025-002 Material Weakness Yes F
1222039 2025-002 Material Weakness Yes F
1222040 2025-002 Material Weakness Yes F
1222041 2025-002 Material Weakness Yes F
1222042 2025-002 Material Weakness Yes F
1222043 2025-002 Material Weakness Yes F
1222044 2025-002 Material Weakness Yes F
1222045 2025-002 Material Weakness Yes F
1222046 2025-002 Material Weakness Yes F
1222047 2025-002 Material Weakness Yes F
1222048 2025-002 Material Weakness Yes F
1222049 2025-002 Material Weakness Yes F
1222050 2025-002 Material Weakness Yes F
1222051 2025-002 Material Weakness Yes F
1222052 2025-002 Material Weakness Yes F
1222053 2025-002 Material Weakness Yes F
1222054 2025-002 Material Weakness Yes F
1222055 2025-002 Material Weakness Yes F
1222056 2025-002 Material Weakness Yes F
1222057 2025-002 Material Weakness Yes F
1222058 2025-002 Material Weakness Yes F
1222059 2025-002 Material Weakness Yes F
1222060 2025-002 Material Weakness Yes F
1222061 2025-002 Material Weakness Yes F
1222062 2025-002 Material Weakness Yes F
1222063 2025-002 Material Weakness Yes F
1222064 2025-002 Material Weakness Yes F
1222065 2025-002 Material Weakness Yes F
1222066 2025-002 Material Weakness Yes F
1222067 2025-002 Material Weakness Yes F
1222068 2025-002 Material Weakness Yes F
1222069 2025-002 Material Weakness Yes F
1222070 2025-002 Material Weakness Yes F
1222071 2025-002 Material Weakness Yes F
1222072 2025-002 Material Weakness Yes F
1222073 2025-002 Material Weakness Yes F
1222074 2025-002 Material Weakness Yes F
1222075 2025-002 Material Weakness Yes F
1222076 2025-002 Material Weakness Yes F
1222077 2025-002 Material Weakness Yes F
1222078 2025-002 Material Weakness Yes F
1222079 2025-002 Material Weakness Yes F
1222080 2025-002 Material Weakness Yes F
1222081 2025-002 Material Weakness Yes F
1222082 2025-002 Material Weakness Yes F
1222083 2025-002 Material Weakness Yes F
1222084 2025-002 Material Weakness Yes F
1222085 2025-002 Material Weakness Yes F
1222086 2025-002 Material Weakness Yes F
1222087 2025-002 Material Weakness Yes F
1222088 2025-002 Material Weakness Yes F
1222089 2025-002 Material Weakness Yes F
1222090 2025-002 Material Weakness Yes F
1222091 2025-002 Material Weakness Yes F
1222092 2025-002 Material Weakness Yes F
1222093 2025-002 Material Weakness Yes F
1222094 2025-002 Material Weakness Yes F
1222095 2025-002 Material Weakness Yes F
1222096 2025-002 Material Weakness Yes F
1222097 2025-002 Material Weakness Yes F
1222098 2025-002 Material Weakness Yes F
1222099 2025-002 Material Weakness Yes F
1222100 2025-002 Material Weakness Yes F
1222101 2025-002 Material Weakness Yes F
1222102 2025-002 Material Weakness Yes F
1222103 2025-002 Material Weakness Yes F
1222104 2025-002 Material Weakness Yes F
1222105 2025-002 Material Weakness Yes F
1222106 2025-002 Material Weakness Yes F
1222107 2025-002 Material Weakness Yes F
1222108 2025-002 Material Weakness Yes F
1222109 2025-002 Material Weakness Yes F
1222110 2025-002 Material Weakness Yes F
1222111 2025-002 Material Weakness Yes F
1222112 2025-002 Material Weakness Yes F
1222113 2025-002 Material Weakness Yes F
1222114 2025-002 Material Weakness Yes F
1222115 2025-002 Material Weakness Yes F
1222116 2025-002 Material Weakness Yes F
1222117 2025-002 Material Weakness Yes F
1222118 2025-002 Material Weakness Yes F
1222119 2025-002 Material Weakness Yes F
1222120 2025-002 Material Weakness Yes F
1222121 2025-002 Material Weakness Yes F
1222122 2025-002 Material Weakness Yes F
1222123 2025-002 Material Weakness Yes F
1222124 2025-002 Material Weakness Yes F
1222125 2025-002 Material Weakness Yes F
1222126 2025-002 Material Weakness Yes F
1222127 2025-002 Material Weakness Yes F
1222128 2025-002 Material Weakness Yes F
1222129 2025-002 Material Weakness Yes F
1222130 2025-002 Material Weakness Yes F
1222131 2025-002 Material Weakness Yes F
1222132 2025-002 Material Weakness Yes F
1222133 2025-002 Material Weakness Yes F
1222134 2025-002 Material Weakness Yes F
1222135 2025-002 Material Weakness Yes F
1222136 2025-002 Material Weakness Yes F
1222137 2025-002 Material Weakness Yes F
1222138 2025-002 Material Weakness Yes F
1222139 2025-002 Material Weakness Yes F
1222140 2025-002 Material Weakness Yes F
1222141 2025-002 Material Weakness Yes F
1222142 2025-002 Material Weakness Yes F
1222143 2025-002 Material Weakness Yes F
1222144 2025-002 Material Weakness Yes F
1222145 2025-002 Material Weakness Yes F
1222146 2025-002 Material Weakness Yes F
1222147 2025-002 Material Weakness Yes F
1222148 2025-002 Material Weakness Yes F
1222149 2025-002 Material Weakness Yes F
1222150 2025-002 Material Weakness Yes F
1222151 2025-002 Material Weakness Yes F
1222152 2025-002 Material Weakness Yes F
1222153 2025-002 Material Weakness Yes F
1222154 2025-002 Material Weakness Yes F
1222155 2025-002 Material Weakness Yes F
1222156 2025-002 Material Weakness Yes F
1222157 2025-002 Material Weakness Yes F
1222158 2025-002 Material Weakness Yes F
1222159 2025-002 Material Weakness Yes F
1222160 2025-002 Material Weakness Yes F
1222161 2025-002 Material Weakness Yes F
1222162 2025-002 Material Weakness Yes F
1222163 2025-002 Material Weakness Yes F
1222164 2025-002 Material Weakness Yes F
1222165 2025-002 Material Weakness Yes F
1222166 2025-002 Material Weakness Yes F
1222167 2025-002 Material Weakness Yes F
1222168 2025-002 Material Weakness Yes F
1222169 2025-002 Material Weakness Yes F
1222170 2025-002 Material Weakness Yes F
1222171 2025-002 Material Weakness Yes F
1222172 2025-002 Material Weakness Yes F
1222173 2025-002 Material Weakness Yes F
1222174 2025-002 Material Weakness Yes F
1222175 2025-002 Material Weakness Yes F
1222176 2025-002 Material Weakness Yes F
1222177 2025-002 Material Weakness Yes F
1222178 2025-002 Material Weakness Yes F
1222179 2025-002 Material Weakness Yes F
1222180 2025-002 Material Weakness Yes F
1222181 2025-002 Material Weakness Yes F
1222182 2025-002 Material Weakness Yes F
1222183 2025-002 Material Weakness Yes F
1222184 2025-002 Material Weakness Yes F
1222185 2025-001 Material Weakness Yes B
1222186 2025-003 Material Weakness Yes I
1222187 2025-004 Material Weakness Yes L

Programs

ALN Program Spent Major Findings
17.720 Disability Employment Policy Development $5.21M Yes 1
93.788 Opioid STR $1.86M Yes 2
93.969 COVID-19 PPHF Geriatric Education Centers $1.14M Yes 0
93.493 Congressional Directives $992,950 Yes 0
93.800 Organized Approaches to Increase Colorectal Cancer Screening $807,756 Yes 0
21.027 COVID-19 Coronavirus State and Local Fiscal Recovery Funds $794,962 Yes 0
93.186 National Research Service Award in Primary Care Medicine $734,628 Yes 2
93.958 Block Grants for Community Mental Health Services $654,760 Yes 0
17.268 H-1B Job Training Grants $651,086 Yes 0
93.850 Improving Epilepsy Programs, Services, and Outcomes through National Partnerships $608,775 Yes 2
93.069 Public Health Emergency Preparedness $585,857 Yes 0
12.007 Military Health System Research $546,688 Yes 2
93.087 Enhance Safety of Children Affected by Substance Abuse $514,770 Yes 0
93.153 Coordinated Services and Access to Research for Women, Infants, Children $504,590 Yes 0
90.601 Northern Border Regional Development $500,000 Yes 0
93.478 CDC will strengthen the U.S. public health's Review Committees $473,789 Yes 0
93.918 Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease $427,998 Yes 0
93.870 Maternal, Infant and Early Childhood Home Visiting Grant $403,276 Yes 0
93.394 Cancer Detection and Diagnosis Research $382,713 Yes 2
93.307 Minority Health and Health Disparities Research $367,139 Yes 2
93.361 Nursing Research $352,379 Yes 2
93.268 COVID-19 Vaccination Program $313,125 Yes 0
93.398 Cancer Research Manpower $266,686 Yes 2
93.061 Innovations in Applied Public Health Research $261,631 Yes 2
16.575 Crime Victim Assistance $261,477 Yes 0
93.127 Injury Prevention and Control Research and State and Community $254,115 Yes 0
93.U01 RPHN Recomp $217,666 Yes 0
93.592 Family Violence Prevention and Services/Discretionary $216,525 Yes 0
20.600 State and Community Highway Safety $193,868 Yes 0
93.991 Block Grants for Prevention Treatment $174,720 Yes 0
93.310 Trans-NIH Research Support $167,560 Yes 2
20.616 National Priority Safety Programs $166,854 Yes 0
93.859 Biomedical Research and Research Training $151,145 Yes 2
93.135 Centers for Research and Demonstration for Health Promotion and Disease Prevention $134,453 Yes 2
93.323 COVID-19 Epidemiology and Laboratory Capacity for Infectious Diseases $127,567 Yes 0
93.865 Child Health and Human Development Extramural Research $95,521 Yes 2
17.280 WIOA Dislocated Worker National Reserve Demonstration Grants $93,619 Yes 0
93.155 COVID-19 Testing and Mitigation $93,208 Yes 0
93.077 Family Smoking Prevention $87,230 Yes 2
93.747 Elder Abuse Prevention Interventions Program $84,915 Yes 0
93.778 Medical Assistance Program $79,300 Yes 0
93.110 Maternal and Child Health Federal Consolidated Programs $79,284 Yes 0
93.113 Environmental Health $73,114 Yes 2
93.213 Research and Training in Complementary and Integrative Health $71,548 Yes 2
93.393 Cancer Cause and Prevention Research $62,336 Yes 2
93.837 Cardiovascular Diseases Research $56,574 Yes 2
93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health $53,120 Yes 2
93.433 ACL National Institute on Disability, Independent Living, and Rehabilitation Research $52,125 Yes 2
93.279 Drug Abuse and Addiction Research Programs $48,384 Yes 2
93.988 Cooperative Agreements for Diabetes Control Programs $45,500 Yes 0
93.889 COVID-19 National Bioterrorism Hospital Preparedness Program $41,451 Yes 0
93.080 Blood Disorder Program: Prevention, Surveillance, and Research $35,188 Yes 0
93.879 Medical Library Assistance $35,082 Yes 2
93.395 Cancer Treatment Research $34,254 Yes 2
93.959 Block Grants for Prevention and Treatment of Substance Abuse $34,113 Yes 0
93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders $31,376 Yes 2
93.224 Health Center Program $28,750 Yes 0
93.866 Aging Research $24,144 Yes 2
93.426 The National Cardiovascular Health Program $23,000 Yes 0
93.243 Substance Abuse and Mental Health Services Projects of Regional and National Significance $21,754 Yes 0
93.226 Research on Healthcare Costs, Quality and Outcomes $19,809 Yes 2
93.838 Lung Diseases Research $17,965 Yes 2
17.289 Community Project Funding $17,442 Yes 0
93.867 Vision Research $16,655 Yes 2
93.242 Mental Health Research Grants $15,991 Yes 2
93.059 Training in General, Pediatric, and Public Health Dentistry $14,372 Yes 0
93.301 Small Rural Hospital Improvement Grant Program $13,832 Yes 0
93.145 HIV-Related Training and Technical Assistance $12,785 Yes 0
93.855 Allergy and Infectious Diseases Research $12,773 Yes 2
12.420 Military Medical Research and Development $12,466 Yes 2
93.350 National Center for Advancing Translational Sciences $8,399 Yes 2
10.902 Natural Resources Conservation Service $8,061 Yes 0
93.173 Research Related to Deafness and Communication Disorders $5,889 Yes 2
93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research $4,674 Yes 2
93.396 Cancer Biology Research $3,869 Yes 2
10.558 Child and Adult Care Food Program $3,712 Yes 0
93.846 Arthritis, Musculoskeletal and Skin Diseases Research $2,785 Yes 2
93.912 Rural Health Care Services $2,613 Yes 0
93.397 Cancer Centers Support Grants $2,349 Yes 2
93.121 Oral Diseases and Disorders Research $1,593 Yes 2
93.353 21st Century Cures Act - Beau Biden Cancer Moonshot $71 Yes 2

Contacts

Name Title Type
QYLXERHDAQL4 John Muhlen Auditee
7745716206 Kevin McGraw Auditor
No contacts on file

Notes to SEFA

1. Basis of Presentation The accompanying schedule of expenditures of federal awards (the “Schedule”) presents the activity of federal award programs administered by Dartmouth-Hitchcock Health and Subsidiaries (the “Dartmouth Health System”) as defined in the notes to the consolidated financial statements and is presented on an accrual basis. During 2025, the Dartmouth Health System changed its fiscal year end from June 30th to September 30th to align all of the System’s members to the same fiscal year end. The purpose of this Schedule is to present a summary of those activities of the Dartmouth Health System for the 15 month period ended September 30, 2025 which have been financed by the United States government (“federal awards”). The Dartmouth Health System obtained approval from its cognizant agency to enclose financial statements for the 12-months ended June 30, 2025 and the 12-months ended September 30, 2025 as part of this reporting package versus consolidated financial statements that cover the 15-month period presented in the Schedule. All activity of the 15-month period ended September 30, 2025 is included in these two sets of 12-month financial statements. For purposes of this Schedule, federal awards include all federal assistance entered into directly between the Dartmouth Health System and the federal government and subawards from nonfederal organizations made under federally sponsored agreements. The information in this Schedule in presented in accordance with the requirements of the Uniform Guidance. Pass-through entity identification numbers and Assistance Listing numbers have been provided where available. Visiting Nurse and Hospice of NH and VT (“VNH”) received a Community Facilities Loan, Assistance Listing #10.766, of which the proceeds were expended in 2018. The VNH had an outstanding balance of $2,170,000 as of September 30, 2025. As this loan was related to a project that was completed in a prior audit period and the terms and conditions do not impose continued compliance requirements other than to repay the loan, we have excluded the outstanding loan balance from the Schedule. Valley Regional Healthcare, Inc. (“VRH”) received a Community Facilities Loan, Assistance Listing #10.766, of which the proceeds were expended in 2017. VRH had an outstanding balance of $16,808,000 as of September 30, 2025. As this loan was related to a project that was completed in a prior audit period and the terms and conditions do not impose continued compliance requirements other than to repay the loan, we have excluded the outstanding loan balance from the Schedule.
2. Indirect Expenses Indirect costs are charged to certain federal grants and contracts at a federally approved predetermined indirect rate, negotiated with the Division of Cost Allocation and therefore we do not use the de minimus indirect cost rate. Indirect costs are included in the reported federal expenditures.
3. Greater Monadnock Regional Public Health Network Services Cheshire Medical Center received a pass-through award from the County of Cheshire, who were themselves a pass-through entity for their award from the New Hampshire Department of Health and Human Services. The award contract between the County of Cheshire and NH DHHS indicates that the award is funded from several Federal Agencies, programs, and Assistance Listing numbers as noted below. The total award amount of $217,666 was not split out by Agency listed below. Accordingly, the total expenditures of $217,666 included on accompanying SEFA for this program are listed as one amount under the Assistance Listing #93.U01. See the Notes to the SEFA for chart/table

Finding Details

2025-002 Equipment Management Cluster: Research and Development Sponsoring Agency: All research and development cluster sponsoring agencies Award Names: All research and development cluster awards Award Numbers: All research and development cluster awards Assistance Listing Title: All research and development cluster assistance listing titles Assistance Listing Number: All research and development cluster assistance listing numbers Award Year: 2024-2025 Pass-through entity: All research and development cluster pass-through entities Criteria According to 2 CFR section 200.313, procedures for managing equipment (including replacement equipment), whether acquired in whole or in part under a Federal award, until disposition takes place will, at a minimum, meet the following requirements: (1) Property records must be maintained that include a description of the property, a serial number or other identification number, the source of funding for the property (including the FAIN), who holds title, the acquisition date, and cost of the property, percentage of Federal participation in the project costs for the Federal award under which the property was acquired, the location, use and condition of the property, and any ultimate disposition data including the date of disposal and sale price of the property. (2) A physical inventory of the property must be taken and the results reconciled with the property records at least once every two years. (3) A control system must be developed to ensure adequate safeguards to prevent loss, damage, or theft of the property. Any loss, damage, or theft must be investigated. (4) Adequate maintenance procedures must be developed to keep the property in good condition. (5) If the non-Federal entity is authorized or required to sell the property, proper sales procedures must be established to ensure the highest possible return. Condition The Dartmouth Health System has not completed a physical inventory of all federally purchased fixed assets at least once during the last two years. The full population of equipment funded with federal research and development dollars, as provided by the Dartmouth Health System, consisted of 10 items with a total historical cost of $186k. Cause In prior years, the Dartmouth Health System did not have a process in place to ensure that all federally funded equipment included in the fixed asset register were included in its clinical engineering database where monitoring of federally funded equipment is tracked. As a result, while the Dartmouth Health System inspected 3 federal assets in FY2024, the complete population of equipment funded with federal research and development dollars were not inspected. The Dartmouth Health system created a federal equipment tracking procedure, and updated property records to include details required by 2 CFR section 200.313, however, the inspection of all identified federal assets was not yet completed. As the corrective action plan was not fully implemented by the end of FY2025, all compliance requirements with respect to federal equipment were not yet satisfied. Effect The Dartmouth Health System's accounting records for its federally purchased fixed assets could be inaccurate as the Dartmouth Health System has not formally verified the existence, current utilization and continued need for all federally funded equipment through this physical inventory process. Questioned Costs None noted. Repeat Finding Yes. This is a repeat of finding 2022-001, 2024-004 and was reported as an open finding in the 2023 Summary Schedule of Prior Audit Findings and Status. Recommendation We recommend that the Dartmouth Health System implement a process to ensure its policies and procedures over equipment management are followed, including the performance of a physical inventory of federally purchased fixed assets at least once every two years in accordance with 2 CFR section 200.313(d)(2). Management’s Views and Corrective Action Plan Management’s Views and Corrective Action Plan is included at the end of this report after the summary schedule of prior audit findings and status.
2025-001 Timeliness of Effort Certification Cluster: Research and Development (also applies to other major programs referenced below) Sponsoring Agency: All research and development cluster sponsoring agencies and Department of Health and Human Services (for the other major program referenced below) Award Names: All research and development cluster awards and Doorway for Substance Use-Related Supports and Services Award Numbers: All research and development cluster awards, Cheshire Medical Center 05-95-920510-7040000 Assistance Listing Title: All research and development cluster assistance listing titles and Opioid STR Assistance Listing Number: All research and development cluster assistance listing numbers and 93.788 Award Year: 2024-2025 Pass-through entity: All research and development cluster pass-through entities and New Hampshire Department of Health and Human Services Criteria 2 CFR 200.430 contains the federal regulatory requirements for internal controls over certifying time expended on sponsored projects. The Dartmouth Health System’s practice is to utilize after-the-fact effort reports to certify that compensation costs charged to federal awards, are reasonable and consistent with the work performed. Actual effort expended on each federal award is certified by a responsible person with suitable means of verification that the work was performed at the end of the specified reporting period. The Dartmouth Health System’s effort certification policy outlines the required deadlines for certifying effort reports related to federal awards. Condition In testing internal controls over effort certifications, we noted the following: · Research and development- 14 effort reports totaling $43.1k of 17 selected effort reports totaling $51.7k were certified/approved outside of allowable timeframe defined by the effort certification policy. Certifications were on average 150 days late. · 93.788- 3 effort reports totaling $8.8k of 16 selected effort reports totaling $36.5k did not include a certification/approval date to determine whether the related effort was attested within the timeframe required by the entity’s effort certification policy. Cause Individuals required to complete quarterly effort certifications did not understand the policy requirements to certify effort in a timely manner. Effect The lack of timely effort certification could result in compensation expenditures charged to federal awards that are not accurate. Questioned Costs None noted. Repeat Finding Yes. This is a repeat of finding 2024-002. Recommendation We recommend that the Dartmouth Health System recommunicate its effort certification policy and provide training to all individuals required to certify effort for federal awards to ensure that the timely approval expectations are understood and adhered to. Management’s Views and Corrective Action Plan Management’s Views and Corrective Action Plan is included at the end of this report after the summary schedule of prior audit findings and status.
2025-003 Suspension & Debarment Cluster: Other major program referenced below Sponsoring Agency: Department of Health and Human Services Award Names: Doorway for Substance Use-Related Supports and Services Award Numbers: Cheshire Medical Center 05-95-920510-7040000 Assistance Listing Title: Opioid STR Assistance Listing Number: 93.788 Award Year: 2024-2025 Pass-through entity: New Hampshire Department of Health and Human Services Criteria Per 2 CFR 200.214, a non-Federal entity must have and use documented procurement procedures and is prohibited from contracting with or making subawards under covered transactions to parties that are suspended or debarred. The Dartmouth Health System’s suspension and debarment policy requires suspension and debarment verifications to be completed for all vendors utilized on federal awards, regardless of expenditure amount. Condition In testing compliance with suspension and debarment requirements, PwC noted that 2 selections totaling $15.9k out of 9 selections tested totaling $53.5k did not have sufficient supporting documentation to evidence that required suspension and debarment procedures were completed prior to the related transaction and payment dates. For the items noted, the suspension and debarment checks were performed after the related transaction dates and payment dates. As a result, the Dartmouth Health System did not demonstrate that vendors were verified as not suspended or debarred before federal funds were disbursed. Management indicated that certain alternative verification procedures may have been performed prior to payment; however, documentation was not maintained to support that such procedures were completed timely. Cause While the Dartmouth Health System’s policy outlines the procedures to be followed for federal purchases, including required suspension and debarment checks, there was turnover within the procurement function for Cheshire Medical Center. Therefore, instances were identified in which a suspension and debarment check was not performed prior to the transaction. Effect The lack of adherence to the suspension and debarment verification policy could result in the Health System conducting business with a vendor that is suspended or debarred. Questioned Costs None noted. Repeat Finding No Recommendation We recommend the Dartmouth Health System ensure that timely suspension and debarment verifications are completed in line with policy. Management’s Views and Corrective Action Plan Management’s Views and Corrective Action Plan is included at the end of this report after the summary schedule of prior audit findings and status.
2025-004 Reporting Cluster: Other major program referenced below Sponsoring Agency: Department of Labor Award Names: RETAIN Demonstration Projects Award Numbers: 1947RTN2-02B Assistance Listing Title: Disability Employment Policy Development Assistance Listing Number: 17.720 Award Year: 2024-2025 Pass-through entity: Vermont Department of Labor Criteria 2 CFR 200.328 requires non-Federal entities to submit financial reports as required by the Federal award. Per the award agreement, quarterly financial reports detailing all expenses to date under the award are due no later than the fifteenth of the month being reported. Condition During testing of reporting requirements for award 17.720, we noted that monthly financial reports were submitted to the sponsoring agency; however, the required standard quarterly financial reports were not submitted. Based on communication from the sponsoring agency, although the information required for the quarterly reports was included within the monthly reports, the sponsoring agency clarified that separate quarterly reports were still required. Cause The Dartmouth Health System misunderstood the reporting requirements under the award and thought the quarterly reporting requirements were satisfied by the monthly reports submitted. Effect The Dartmouth Health System did not submit the quarterly financial reports required per the award agreement and was not in compliance with reporting requirements. Questioned Costs None noted. Repeat Finding No Recommendation The Dartmouth Health System should ensure that submission of reports is performed as stated within agreed-upon award agreements and should retroactively submit the quarterly reports that were not submitted. Management’s Views and Corrective Action Plan Management’s Views and Corrective Action Plan is included at the end of this report after the summary schedule of prior audit findings and status.